GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

GRN-300 overview

GRN-300 is under development for the treatment of solid tumors, recurrent ovarian cancer, endometrial cancer, primary peritoneal cancer, fallopian tube cancer, triple-negative breast cancer, prostate cancer, acute myeloid leukemia (AML), diffuse large B-cell lymphoma and lung cancer. It is administered through oral route. It acts by targeting serine/threonine-protein kinase (SIK2) and serine/threonine-protein kinase (SIK3). The drug candidate is developed based on fragment-field drug design (FFDD) technology platform.

Greenfire Bio overview

Greenfire Bio (Greenfire) is a life science company that builds a diversified product pipeline by developing early-stage assets. The company acquires, licenses, partners and invests in differentiated pre-clinical oearly clinical stage medical products to bridge the translational medicine gap and accelerate development. Its lead product candidate GRN-300, an orally bioavailable small molecule dual inhibitor of salt inducible kinases 2 and 3 (SIK2, SIK3) for the treatment ovarian cancer. Greenfire is also evaluating drugs targeting triple-negative breast cancer (TNBC), prostate, diffuse large B-cell lymphoma (DLBCL), melanoma and AML cancers. Greenfire is headquartered in Austin, Texas, the US.

For a complete picture of GRN-300’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.